{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T08:46:00Z","timestamp":1793781960787,"version":"4.6.1"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:00:00Z","timestamp":1613347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Knowledge of the real-world effectiveness and safety of tofacitinib for ulcerative colitis (UC) is relevant to confirm the benefit observed in clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This systematic review and meta-analysis evaluated the real-world effectiveness of tofacitinib for moderate to severely active UC. The primary outcome was clinical remission evaluated at week 8, weeks 12 to 16, and month 6. Secondary outcomes were response, corticosteroid-free remission, mucosal healing, colectomy, and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seventeen studies with a total of 1162 patients with UC were included. Remission (11 studies) was achieved in 34.7% of patients at week 8 (95% confidence interval [CI], 24.4%-45.1%), 47% at weeks 12 to 16 (95% CI, 40.3%-53.6%), and 38.3% at month 6 (95% CI, 29.2%-47.5%) at month 6 duplicated. Response was achieved in 62.1%, 64.2%, 50.8%, and 41.8% of patients at week 8, weeks 12 to 16, month 6, and month 12, respectively. Corticosteroid-free remission (5 studies) was achieved in 38.4%, 44.3%, 33.6%, and 31% of patients at week 8, weeks 12 to 16, month 6, and month 12, respectively. Mucosal healing was achieved in 48.3% and 45.3% of patients at week 8 and weeks 12 to 16, respectively. Patients who were biologic-na\u00efve (11.6%) had a significantly higher rate of response at week 8 (1.38; 95% CI, 1.03-1.84). The incidence rates of serious adverse events and herpes zoster was 8.9 and 6.9 per 100 patient-years, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This meta-analysis of real-world studies confirms the effectiveness of tofacitinib in a highly refractory population of patients with moderate to severely active UC. Tofacitinib showed an acceptable safety profile. These findings were consistent with clinical trials and further support the use of tofacitinib in UC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izab011","type":"journal-article","created":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T16:19:13Z","timestamp":1613405953000},"page":"32-40","source":"Crossref","is-referenced-by-count":134,"title":["Real-World Effectiveness and Safety of Tofacitinib in Patients With Ulcerative Colitis: Systematic Review With Meta-Analysis"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9166-7350","authenticated-orcid":false,"given":"Carlos","family":"Taxonera","sequence":"first","affiliation":[{"name":"From the Inflammatory Bowel Disease Unit, Gastroenterology Department, Hospital Cl\u00ednico San Carlos and Instituto de Investigaci\u00f3n del Hospital Cl\u00ednico San Carlos , Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Olivares","sequence":"additional","affiliation":[{"name":"From the Inflammatory Bowel Disease Unit, Gastroenterology Department, Hospital Cl\u00ednico San Carlos and Instituto de Investigaci\u00f3n del Hospital Cl\u00ednico San Carlos , Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Alba","sequence":"additional","affiliation":[{"name":"From the Inflammatory Bowel Disease Unit, Gastroenterology Department, Hospital Cl\u00ednico San Carlos and Instituto de Investigaci\u00f3n del Hospital Cl\u00ednico San Carlos , Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,2,15]]},"reference":[{"key":"2022091221341731300_CIT0001","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1021\/jm401490p","article-title":"Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases","volume":"57","author":"Clark","year":"2014","journal-title":"J Med Chem."},{"key":"2022091221341731300_CIT0002","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.gtc.2014.05.011","article-title":"Update on Janus kinase antagonists in inflammatory bowel disease","volume":"43","author":"Boland","year":"2014","journal-title":"Gastroenterol Clin North Am."},{"key":"2022091221341731300_CIT0003","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med."},{"key":"2022091221341731300_CIT0004","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.cgh.2018.11.035","article-title":"Safety of tofacitinib for treatment of ulcerative colitis, based on 4.4 years of data from global clinical trials","volume":"17","author":"Sandborn","year":"2019","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2022091221341731300_CIT0005","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/apt.15689","article-title":"Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry","volume":"51","author":"Biemans","year":"2020","journal-title":"Aliment Pharmacol Ther."},{"key":"2022091221341731300_CIT0006","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/ecco-jcc\/jjaa075","article-title":"Real-world effectiveness of tofacitinib for moderate to severe ulcerative colitis: a multicentre UK experience","volume":"14","author":"Honap","year":"2020","journal-title":"J Crohns Colitis."},{"key":"2022091221341731300_CIT0007","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.dld.2019.10.003","article-title":"Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis","volume":"52","author":"Lair-Mehiri","year":"2020","journal-title":"Dig Liver Dis."},{"key":"2022091221341731300_CIT0008","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"Plos Med."},{"key":"2022091221341731300_CIT0009"},{"key":"2022091221341731300_CIT0010","author":"Higgins"},{"key":"2022091221341731300_CIT0011","article-title":"Rapid prediction of 1-year efficacy of tofacitinib for treating refractory ulcerative colitis","author":"Shimizu","year":"2020","journal-title":"Intest Res."},{"key":"2022091221341731300_CIT0012","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1007\/s10620-019-05492-y","article-title":"Real-world experience with tofacitinib in IBD at a tertiary center","volume":"64","author":"Weisshof","year":"2019","journal-title":"Dig Dis Sci."},{"key":"2022091221341731300_CIT0013","article-title":"Tofacitinib in ulcerative colitis: real-world evidence from Eneida Registry","author":"Chaparro","year":"2020","journal-title":"J Crohns Colitis."},{"key":"2022091221341731300_CIT0014","first-page":"S149","article-title":"Induction therapy with tofacitinib in patients with moderate-to-severe ulcerative colitis","volume":"30 Supplement 3","author":"Alatab","year":"2019","journal-title":"Turk J Gastroenterol."},{"key":"2022091221341731300_CIT0015","doi-asserted-by":"crossref","first-page":"S-1208","DOI":"10.1016\/S0016-5085(20)33682-9","article-title":"Tofacitinib induces clinical and endoscopic remission in biologic refractory ulcerative colitis patients","volume":"158","author":"Cremer","year":"2020","journal-title":"Gastroenterology."},{"key":"2022091221341731300_CIT0016","doi-asserted-by":"crossref","first-page":"S-169","DOI":"10.1016\/S0016-5085(19)37214-2","article-title":"Real-world safety of tofacitinib in inflammatory bowel diseases: a multi-center study","volume":"156","author":"Deepak","year":"2019","journal-title":"Gastroenterology."},{"key":"2022091221341731300_CIT0017","first-page":"S494","article-title":"Frequency and causes of prolongation of the induction course of tofacitinib in patients with ulcerative colitis in conditions of real clinical practice","volume":"14(Supplement_1)","author":"Knyazev","journal-title":"J Crohn\u2019s Colitis."},{"key":"2022091221341731300_CIT0018","first-page":"S348","article-title":"Tofacitinib induction efficiency and intracellular cytokine dynamics in ulcerative colitis: results from clinical practice","volume":"14(Supplement_1)","author":"Kolar","journal-title":"J Crohn\u2019s Colitis."},{"key":"2022091221341731300_CIT0019","doi-asserted-by":"crossref","first-page":"S-168","DOI":"10.1016\/S0016-5085(19)37213-0","article-title":"Real-world effectiveness of tofacitinib in ulcerative colitis; a multi-center study","volume":"156","author":"Patel","year":"2019","journal-title":"Gastroenterology."},{"key":"2022091221341731300_CIT0020","doi-asserted-by":"crossref","first-page":"S545","DOI":"10.1093\/ecco-jcc\/jjz203.791","article-title":"Efficacy of tofacitinib in patients with ulcerative colitis after previous ineffective biological therapies","volume":"14","author":"Rutka","year":"2020","journal-title":"J Crohn\u2019s Colitis."},{"key":"2022091221341731300_CIT0021","doi-asserted-by":"crossref","first-page":"S-952","DOI":"10.1016\/S0016-5085(20)33058-4","article-title":"Endoscopic and histologic outcome in tofacitinib treated refractory moderate-to-severe ulcerative colitis: a prospective real-life cohort","volume":"158","author":"Verstockt","year":"2020","journal-title":"Gastroenterology."},{"key":"2022091221341731300_CIT0022","doi-asserted-by":"crossref","first-page":"S535","DOI":"10.1093\/ecco-jcc\/jjz203.776","article-title":"Efficacy including rapid response and safety of tofacitinib in Japanese patients with ulcerative colitis: a preliminary investigation in a specialised ibd centre","volume":"14","author":"Watanabe","year":"2020","journal-title":"J Crohn\u2019s Colitis."},{"key":"2022091221341731300_CIT0023","doi-asserted-by":"crossref","first-page":"S444","DOI":"10.1093\/ecco-jcc\/jjz203.641","article-title":"Efficacy of tofacitinib for the treatment of moderate-to-severe ulcerative colitis: real-world data","volume":"14","author":"Xiao","year":"2020","journal-title":"J Crohn\u2019s Colitis."},{"key":"2022091221341731300_CIT0024","doi-asserted-by":"crossref","first-page":"S545","DOI":"10.1093\/ecco-jcc\/jjz203.790","article-title":"Efficacy and safety of tofacitinib in patients with moderate-to-severe ulcerative colitis: a real-world retrospective study","volume":"14","author":"Yoshimura","year":"2020","journal-title":"J Crohn\u2019s Colitis."},{"key":"2022091221341731300_CIT0025","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.cgh.2018.11.022","article-title":"Efficacy of induction therapy with high-intensity tofacitinib in 4 patients with acute severe ulcerative colitis","volume":"17","author":"Berinstein","year":"2019","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2022091221341731300_CIT0026","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/ecco-jcc\/jjaa018","article-title":"Tofacitinib for rescue therapy in acute severe ulcerative colitis: a real-world experience","volume":"14","author":"Kotwani","year":"2020","journal-title":"J Crohns Colitis."},{"key":"2022091221341731300_CIT0027","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1093\/ibd\/izaa157","article-title":"Tofacitinib in acute severe ulcerative colitis\u2014a real-world tertiary center experience","volume":"26","author":"Honap","year":"2020","journal-title":"Inflamm Bowel Dis."},{"key":"2022091221341731300_CIT0028","author":"European Medicines Agency"},{"key":"2022091221341731300_CIT0029","author":"U.S. Food & Drug Administration."},{"key":"2022091221341731300_CIT0030","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","article-title":"Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis","volume":"142","author":"Sandborn","year":"2012","journal-title":"Gastroenterology."},{"key":"2022091221341731300_CIT0031","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.dld.2018.11.002","article-title":"Effectiveness of golimumab in ulcerative colitis: a review of the real world evidence","volume":"51","author":"Olivera","year":"2019","journal-title":"Dig Liver Dis."},{"key":"2022091221341731300_CIT0032","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1097\/MIB.0000000000001144","article-title":"Clinical outcomes of golimumab as first, second or third anti-TNF agent in patients with moderate-to-severe ulcerative colitis","volume":"23","author":"Taxonera","year":"2017","journal-title":"Inflamm Bowel Dis."},{"key":"2022091221341731300_CIT0033","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med."},{"key":"2022091221341731300_CIT0034","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1007\/s00535-018-1480-0","article-title":"Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease","volume":"53","author":"Schreiber","year":"2018","journal-title":"J Gastroenterol."},{"key":"2022091221341731300_CIT0035","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/apt.15555","article-title":"Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open","volume":"51","author":"Sands","year":"2020","journal-title":"Aliment Pharmacol Ther."},{"key":"2022091221341731300_CIT0036","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/ajg.2015.233","article-title":"Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target","volume":"110","author":"Peyrin-Biroulet","year":"2015","journal-title":"Am J Gastroenterol."},{"key":"2022091221341731300_CIT0037","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1053\/j.gastro.2013.05.048","article-title":"Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology."},{"key":"2022091221341731300_CIT0038","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s10620-016-4398-5","article-title":"Adalimumab maintenance treatment in ulcerative colitis: outcomes by prior anti-TNF use and efficacy of dose escalation","volume":"62","author":"Taxonera","year":"2017","journal-title":"Dig Dis Sci."},{"key":"2022091221341731300_CIT0039","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3899\/jrheum.130683","article-title":"Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies","volume":"41","author":"Wollenhaupt","year":"2014","journal-title":"J Rheumatol."},{"key":"2022091221341731300_CIT0040","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1136\/annrheumdis-2016-210457","article-title":"Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5\u2005years: integrated analysis of data from the global clinical trials","volume":"76","author":"Cohen","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"2022091221341731300_CIT0041","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.semarthrit.2016.05.014","article-title":"Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor","volume":"46","author":"Charles-Schoeman","year":"2016","journal-title":"Semin Arthritis Rheum."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/28\/1\/32\/45808447\/izab011.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/28\/1\/32\/45808447\/izab011.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T17:35:52Z","timestamp":1663004152000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/28\/1\/32\/6136180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,15]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,2,15]]},"published-print":{"date-parts":[[2022,1,5]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izab011","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,1,1]]},"published":{"date-parts":[[2021,2,15]]}}}